Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 1 diabetes mellitus (T1DM) is a rare, irreversible immune-related adverse event reported in patients receiving treatment with immune checkpoint inhibitors (ICI). However, clinical risk factors for ICI-induced T1DM (ICI-T1DM) and its impact on survival in patients remain unknown. RESEARCH DESIGN AND METHODS: We used Optum's Clinformatics Data Mart database for assessment of the incidence and characteristics of T1DM in a large de-identified cohort of patients treated with ICI between 2017 and 2020. We applied Fine-Gray and cause-specific hazard models to study associations between patient/treatment characteristics and ICI-T1DM and applied the Cox model with ICI-T1DM as a time-varying covariate to assess the impact of ICI-T1DM on survival. RESULTS: ICI-T1DM was observed in 261 of 30,337 (0.86%) patients. Dual use of antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) was associated with increasing risk of ICI-T1DM (hazard ratio [HR] 1.62; 95% CI 1.15-2.26) vs. anti-PD-L1 or anti-PD-1 alone. Younger age (HR 1.19 for every 5-year decrease; 95% CI 1.13-1.25) and preexisting non-T1DM diabetes (HR 4.48; 95% CI 3.45-5.83) were also associated with higher risk of ICI-T1DM. Conversely, prior use of immunosuppressive medications (HR 0.57; 95% CI 0.34-0.95) was associated with lower incidence of ICI-T1DM, but part of its protective effect may be due to the increased mortality rate. Development of ICI-T1DM does not seem to significantly impact patient survival. CONCLUSIONS: The risk of ICI-T1DM is associated with the type of ICI therapy, patient age, and preexisting non-T1DM diabetes. These data may help guide risk assessment and screening practices for patients during ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fulminant onset of type 1 diabetes can occur, with DKA and low or undetectable levels of C-peptide as a marker of endogenous b -cell function (64 -66).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017) · Medical Care · doi:10.1097/mlr.0000000000000735 · Cited by 827
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Imagawa, A., Hanafusa, T., Miyagawa, J.-I., & Matsuzawa, Y. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420501 · Cited by 652
Clark, A., Wells, C. A., BULEY, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J. S., Holman, R. R., & Turner, R. C. (1988) · PubMed · Cited by 649
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290
Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
Anderson, J. R., Cain, K. C., & Gelber, R. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1000 · Cited by 228
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228
Rui, J., Deng, S., Arazi, A., Perdigoto, A. L., Liu, Z., & Herold, K. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.01.005 · Cited by 207
Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
Akturk, H. K., Kahramangil, D., Sarwal, A., Hoffecker, L., Murad, M. H., & Michels, A. W. (2019) · Diabetic Medicine · doi:10.1111/dme.14050 · Cited by 188
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Quandt, Z., Young, A., & Anderson, M. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13424 · Cited by 184
Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V. H. M., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 139
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
Wright, J. J., Salem, J.-E., Johnson, D. B., Lebrun-Vignes, B., Stamatouli, A., Thomas, J. W., Herold, K. C., Moslehi, J., & Powers, A. C. (2018) · Diabetes Care · doi:10.2337/dc18-1465 · Cited by 126
Kehl, K. L., Yang, S., Awad, M. M., Palmer, N., Kohane, I. S., & Schrag, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02321-z · Cited by 104
Marchand, L., Thivolet, A., Dalle, S., Chikh, K., Reffet, S., Vouillarmet, J., Fabien, N., Cugnet‐Anceau, C., & Thivolet, C. H. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1234-8 · Cited by 100
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity
Aktürk, H. K., Alkanani, A. K., Zhao, Z., Yu, L., & Michels, A. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01430 · Cited by 54
Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome
Perdigoto, A. L., Quandt, Z., Anderson, M. S., & Herold, K. C. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30072-5 · Cited by 48
Zezza, M., Kosinski, C., Mekoguem, C., Marino, L., Chtioui, H., Pitteloud, N., & Lamine, F. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0467-z · Cited by 46
Immunotherapy for the Prevention and Treatment of Type 1 Diabetes
Bresson, D., & von Herrath, M. (2009) · Diabetes Care · doi:10.2337/dc09-0373 · Cited by 42
Shiba, M., Inaba, H., Ariyasu, H., Kawai, S., Inagaki, Y., Matsuno, S., Iwakura, H., Yamamoto, Y., Nishi, M., & Akamizu, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9518-17 · Cited by 42
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 36
PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes
Martinov, T., Spanier, J. A., Pauken, K. E., & Fife, B. T. (2016) · Immunoendocrinology · doi:10.14800/ie.1164 · Cited by 25
Shimada, K., Yamamoto, H., Nakatani, E., Kumamaru, H., Nishimura, S., Ichihara, N., Hirahara, N., Mori, K., Kotani, M., Miyachi, Y., et al. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.12.009 · Cited by 21
Research works printed but not linked: 1
- 19. Nicolaides NC, Pavlaki AN, Alexandra MAM, et al. Glucocorticoid therapy and adrenal suppression. In Endoxtext. Feingold KR, Anawalt B, Boyce A, et al., Eds. South Dartmouth, MA, MDText.com, Inc., 2015
Cited by
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Cho, Y. K., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0072 · Cited by 62
Metadata
- Authors
- Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., & Zhao, L.
- Affiliations
- University of Michigan (US)
- Biostatistics and Biomathematics Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Ann Arbor, MI
- Department of Anesthesiology, University of Michigan, Ann Arbor, MI
- Corresponding author
- Zhao, Lili
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-03-03
- Volume
- 45
- Issue
- 5
- Pages
- 1170-1176
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9174959
- OpenAlex
- W4214883428
- Cited by
- 93
- References
- 33
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 26 · 2023: 17 · 2022: 6
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA046592)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, immune-related adverse events, CTLA-4, PD-1, PD-L1, pregestational diabetes, immunosuppressants, risk factors, survival, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Diabetes Mellitus, Type 1, Humans, Retrospective Studies, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.